...
首页> 外文期刊>Journal of Cancer Therapy >The Reliability of Assessment of Ki-67 Expression on Core Needle Biopsy and the Surgical Specimens of Invasive Breast Cancer: Comparison of Local Pathologists’ Assessment and Central Review
【24h】

The Reliability of Assessment of Ki-67 Expression on Core Needle Biopsy and the Surgical Specimens of Invasive Breast Cancer: Comparison of Local Pathologists’ Assessment and Central Review

机译:核心针穿刺活检和浸润性乳腺癌手术标本评估Ki-67表达的可靠性:本地病理学家评估和中央评价的比较

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Purpose: The aim of this study was to assess the reliability of Ki-67 expression on core needle biopsy (CNB) and the surgical specimens of invasive breast cancer. We examined the concordance rate of Ki-67 expressions, hormone receptors, and human epidermal growth factor receptor 2 (HER2) status from a CNB with from a surgery in invasive breast cancer. Methods: A retrospective study was conducted on a clinical database of patients who underwent surgery for early breast cancer. Of these, 193 patients who underwent CNB before the surgery were enrolled. A cut-off value of 20% was used for Ki-67-positive criteria. Expression of estrogen receptor (ER), progesterone receptor (PgR), and HER2 were examined and compared with that of Ki-67. To evaluate discordance between the pathologists’ earlier assessments, we re-examined Ki-67 expression among the Ki-67 discordant group in a central laboratory. Results: The concordance rate for Ki-67 expression between the two specimen types was 77.7%, which was significantly lower than that for ER, PgR, and HER2 expression (95.9%, 88.1%, and 91.6%, respectively). The concordance rate for re-examined Ki-67 expression among the Ki-67 discordant group improved to 93.8% and was not significantly different from that for the other receptors. Conclusion: The concordance rate for Ki-67 expression between biopsy and surgical specimens was significantly lower than that for ER, PgR, and HER2 expressions, but re-examination of Ki-67 expression in a central laboratory revealed no significant difference among the receptors, suggesting the need for standard pathological assessment of Ki-67 expression for clinical use as a predictive marker of breast cancer.
机译:目的:本研究的目的是评估Ki-67表达在核心针穿刺活检(CNB)和浸润性乳腺癌手术标本中的可靠性。我们检查了CNB与浸润性乳腺癌手术中Ki-67表达,激素受体和人类表皮生长因子受体2(HER2)状态的符合率。方法:回顾性研究在接受早期乳腺癌手术的患者的临床数据库中进行。在这些患者中,有193例在手术前接受了CNB治疗。 Ki-67阳性标准的临界值为20%。检查雌激素受体(ER),孕激素受体(PgR)和HER2的表达,并与Ki-67进行比较。为了评估病理学家先前评估之间的不一致,我们在中心实验室中重新检查了Ki-67不和谐小组中的Ki-67表达。结果:两种标本之间Ki-67表达的一致性率为77.7%,显着低于ER,PgR和HER2表达的一致性(分别为95.9%,88.1%和91.6%)。 Ki-67不一致组之间重新检查Ki-67表达的一致性比率提高到93.8%,与其他受体的一致性没有显着差异。结论:活检组织和手术标本之间Ki-67表达的一致性率显着低于ER,PgR和HER2表达,但是在中心实验室对Ki-67表达的重新检查显示受体之间没有显着差异,提示需要对Ki-67表达进行标准病理评估以用于临床,作为乳腺癌的预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号